Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Juknat, Ana ^a   Pietr, Maciej ^b   Kozela, Ewa ^a,b   Rimmerman, Neta ^a,b   Levy, Rivka ^b   Gao, Fuying ^c   Coppola, Giovanni ^c   Geschwind, Daniel ^c   Vogel, Zvi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CANNABIDIOL; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DRONABINOL; DUAL SPECIFICITY PHOSPHATASE 2; GLUTATHIONE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; ATF4 GENE; CDKN2B GENE; CELL ACTIVATION; CELLULAR STRESS RESPONSE; CISH GENE; CONTROLLED STUDY; DRUG TARGETING; DUSP1 GENE; DUSP2 GENE; DUSP8 GENE; GADD45A GENE; GENE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; HMOX1 GENE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MICROGLIA; NONHUMAN; NRF2 GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; SOCS3 GENE; STAT1 GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRIB3 GENE;

ANIMALS; CANNABINOIDS; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

CANNABIS SATIVA;

EID: 84876556444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061462     Document Type: Article

References (76)

1. Kogan NM, Mechoulam R, (2007) Cannabinoids in health and disease. Dialogues Clin Neurosci 9: 413-430.
2. Hill AJ, Williams CM, Whalley BJ, Stephens GJ, (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics 133: 79-97.
3. Pertwee RG, (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95: 165-174.
4. Guzman M, (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745-755.
5. Di Marzo V, De Petrocellis L, (2006) Plant, synthetic and endogenous cannabinoids in medicine. Ann Rev Med 57: 553-574.
6. Gowran A, Noonan J, Campbell VA, (2011) The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neuroscience & Therapeutics 17: 637-644.
7. Cabral GA, Staab A, (2005) Effects on the immune system. Handb Exp Pharmacol 168: 385-423.
8. Klein TW, Cabral GA, (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1: 50-64.
9. Ashton JC, (2007) Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 8: 373-384.
10. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P, (2010) Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215: 598-605.
11. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, et al. (2010) Cannabinoids Δ9-tetrahydrocannabinol and cannabidiol differentially inhibit the LPS-activated NF-κB and IFNβ/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285: 1616-1625.
12. Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, et al. (2011) Cannabidiol inhibits pathogenic T-cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in mice. Brit J Pharmacol 163: 1507-1519.
13. Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, et al. (2012) Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Brit J Pharmacol 165: 2512-2528.
14. Juknat A, Rimmerman N, Levy R, Vogel Z, Kozela E, (2012) Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochem Int 61: 923-930.
15. van der Stelt M, Di Marzo V, (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 7: 37-50.
16. Velasco G, Sánchez C, Guzmán M, (2012) Towards the use of cannabinoids as antitumor agents. Nature Rev Cancer 12: 436-444.
17. Wu HY, Goble K, Mecha M, Wang CC, Huang CH, et al. (2012) Cannabidiol-induced apoptosis in murine microglial cells through lipid raft. Glia 60: 1182-1190.
18. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F, (2008) CB2 receptors in the brain: role in central immune function. Brit J Pharmacol 153: 240-251.
19. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
20. Stella N, (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas. Glia 58: 1017-1030.
21. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, et al. (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40: 3228-3233.
22. Cabral GA, Griffin-Thomas L, (2009) Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11: e3.
23. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO, (2007) Cannabidiol-recent advances. Chem Biodivers 4: 1678-1692.
24. Scuderi C, De Filippis D, Iuvone T, Blasio A, Steardo A, et al. (2009) Cannabidiol in Medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23: 597-602.
25. Booz GW, (2011) Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biology & Medicine 51: 1054-1061.
26. Fernandez-Ruiz J, Sagredo O, Pazos MR, Garcia C, Pertwee R, et al. (2013) Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Brit J Clin Pharmacol 75: 323-333.
27. Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, et al. (2012) Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death and Disease 3: e331.
28. Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, et al. (2012) Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63: 776-783.
29. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
30. Rimmerman N, Kozela E, Levy R, Vogel Z, Juknat A (2013) Cannabinoid signaling through non CB1/non CB2 GPCR targets in microglia. In: Abood ME, Sorensen RG, Stella N, editors.endoCANNABINOIDS.Actions at non-CB1/CB2 cannabinoid receptors.Series: The Receptors, Vol. 24, pp.143-171. Springer Verlag, New York.
31. Rimmerman N, Juknat A, Kozela E, Levy R, Bradshaw HB, et al. (2011) The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells. Cell Mol Neurobiol 31: 921-930.
32. Srivastava MD, Srivastava BI, Brouhard B, (1998) Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40: 179-185.
33. Cabral GA, Dove Pettit DA, (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83: 116-123.
34. Klein TW, Newton C, Larsen K, Chou J, Perkins I, et al. (2004) Cannabinoid receptors and T helper cells. J Neuroimmunol 147: 91-94.
35. Puffenbarger RA, Boothe AC, Cabral GA, (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29: 58-69.
36. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, et al. (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79.
37. Carrier EJ, Auchampach JA, Hillard CJ, (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 7895-7900.
38. O′Sullivan SE, (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582.
39. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, et al. (2011) Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLOS One 6: e28668.
40. De Petrocellis L, Di Marzo V, (2010) Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids and synthetic cannabimimetics: focus on G-protein coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5: 103-121.
41. Graeber MB, Streit WJ, (2010) Microglia: biology and pathology. Acta Neuropathol 119: 89-105.
42. Saijo K, Glass CK, (2011) Microglial cell origin and phenotypes in health and disease. Nature Rev Immunol 11: 775-787.
43. Schwartz M, Shechter R, (2010) Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 6: 405-410.
44. Lund S, Christensen KV, Hedtjarn M, Mortensen AL, Hagberg H, et al. (2006) The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol 180: 71-87.
45. Thomas DM, Francescutti-Verbeem DM, Kuhn DM, (2006) Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. Faseb J 20: 515-517.
46. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, et al. (2005) A network-based analysis of systemic inflammation in humans. Nature 437: 1032-1037.
47. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. Nat Genet. 25: 25-29.
48. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc 4: 44-57.
49. Baird TD, Wek RC, (2012) Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism. Adv Nutr 3: 307-321.
50. Ben-Neriah Y, Karin M, (2011) Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunol 12: 715-723.
51. Dietrich C, Kaina B, (2010) The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31: 1319-1328.
52. Banisor I, Leist TP, Kalman B, (2005) Involvement of β-chemokines in the development of inflammatory demyelination. J Neuroinflammation 2: 7.
53. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, et al. (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. PNAS 97: 9561-9566.
54. Sancho D, Gómez M, Viedma F, Esplugues E, Gordón-Alonso M, et al. (2003) CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Invest 112: 872-882.
55. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, et al. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94: 11514-11519.
56. Lee S, Lee S, Kim JH, Kim JH, Seo JW, et al. (2011) Lipocalin-2 Is a chemokine inducer in the central nervous system. Role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration. J Biol Chem 286: 43855-43870.
57. Lee W-K, Thevenod F, (2006) A role for mitochondrial aquaporins in cellular life-and-death decisions? Am J Physiol Cell Physiol291: C195- C202.
58. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, et al. (2006) Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 7: 274-283.
59. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, et al. (2009) Differential changes in GPR55 during microglial activation. FEBS Letters 583: 2071-2076.
60. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, et al. (2010) N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
61. Rimmerman N, Bradshaw HB, Kozela E, Levy R, Juknat A, et al. (2012) Compartmentalization of endocannabinoids into lipid rafts devoid of caveolin-1 in a microglial cell line. Brit J Pharmacol 165: 2436-2449.
62. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, et al. (2004) Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem 279: 42703-42708.
63. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H, (2005) TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J 24: 1243-1255.
64. Du K, Herzig S, Kulkarni RN, Montminy M, (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300: 1574-1577.
65. Wu M, Xu LG, Zhai Z, Shu HB, (2003) SINK is a p65-interacting negative regulator of NF-kappaB-dependent transcription. J Biol Chem 278: 27072-27079.
66. Sizemore N, Leung S, Stark GR, (1999) Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19: 4798-4805.
67. Dos Santos S, Delattre AI, De Longueville F, Bult H, Raes M, (2007) Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kappaB and PI3K/mTOR signaling pathways. Ann N Y Acad Sci 1096: 70-77.
68. Kim J, Cha Y-N, Surh Y-J, (2010) A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 690: 12-23.
69. Takahashi Y, Ohoka N, Hayashi H, Sato R, (2008) Trb3 suppresses adipocyte differentiation by negatively regulating PPARγ transcriptional activity. J Lipid Res 49: 880-892.
70. O′Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA, (2009) Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612: 61-68.
71. Necela BM, Su W, Thompson EA, (2008) Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages. Immunology 125: 344-358.
72. Nguyen T, Sherratt PJ, Nioi P, Yang CS, Pickett CB, (2005) Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 280: 32485-32492.
73. Talalay P, Dinkova-Kostova AT, Holtzclaw WD, (2003) Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul 43: 121-134.
74. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, et al. (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 16: 61-71.
75. Liby KT, Yore MM, Sporn MB, (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369.
76. Tanaka T, De Luca LM, (2009) Therapeutic potential of rexinoids in cancer prevention and treatment. Cancer Res 69: 4945-4947.